Mark is the founder and CEO of Medicines Development for Global Health, a small Melbourne based not-for-profit drug development company. Passionately focused on developing drugs for diseases with high unmet need he has led his organisation from the licensing of moxidectin, an abandoned drug development program, through a full development program in river blindness. This disease impacts around 18 million people in Sub-Saharan Africa and causes major morbidity and mortality. The efforts of Mark and his team resulted in an FDA Approval of moxidectin in 2018. He was nominated for Victorian Australian of the Year and received the award on 23 October.

CTx is privileged to have Mark, as part of its team, leading its RP2 program which is directed at developing new clinical models to develop drugs for early stage metastasis. CTx extends its warmest congratulations to Mark on this well-deserved recognition.

Read the full article here